GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (XSWX:OBSN) » Definitions » EBITDA Margin %

ObsEva (XSWX:OBSN) EBITDA Margin % : 161.52% (As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is ObsEva EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ObsEva's EBITDA for the three months ended in Dec. 2022 was CHF29.55 Mil. ObsEva's Revenue for the three months ended in Dec. 2022 was CHF18.29 Mil. Therefore, ObsEva's EBITDA margin for the quarter that ended in Dec. 2022 was 161.52%.


ObsEva EBITDA Margin % Historical Data

The historical data trend for ObsEva's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva EBITDA Margin % Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only - - - -219.27 -102.22

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.64 - - - 161.52

Competitive Comparison of ObsEva's EBITDA Margin %

For the Biotechnology subindustry, ObsEva's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ObsEva's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ObsEva's EBITDA Margin % falls into.



ObsEva EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ObsEva's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-18.7/18.294
=-102.22 %

ObsEva's EBITDA Margin % for the quarter that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2022 )/Revenue (Q: Dec. 2022 )
=29.548/18.294
=161.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ObsEva  (XSWX:OBSN) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


ObsEva EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ObsEva's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva (XSWX:OBSN) Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva (XSWX:OBSN) Headlines

No Headlines